BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 29278302)

  • 1. Monophosphoryl Lipid A-Adjuvanted Virosomes with Ni-Chelating Lipids for Attachment of Conserved Viral Proteins as Cross-Protective Influenza Vaccine.
    Dong W; Bhide Y; Marsman S; Holtrop M; Meijerhof T; de Vries-Idema J; de Haan A; Huckriede A
    Biotechnol J; 2018 Apr; 13(4):e1700645. PubMed ID: 29278302
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increased Protein Degradation Improves Influenza Virus Nucleoprotein-Specific CD8+ T Cell Activation In Vitro but Not in C57BL/6 Mice.
    Altenburg AF; van de Sandt CE; van Trierum SE; De Gruyter HLM; van Run PRWA; Fouchier RAM; Roose K; Saelens X; Volz A; Sutter G; de Vries RD; Rimmelzwaan GF
    J Virol; 2016 Nov; 90(22):10209-10219. PubMed ID: 27581985
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of monophosphoryl lipid A as adjuvant for pulmonary delivered influenza vaccine.
    Patil HP; Murugappan S; ter Veer W; Meijerhof T; de Haan A; Frijlink HW; Wilschut J; Hinrichs WL; Huckriede A
    J Control Release; 2014 Jan; 174():51-62. PubMed ID: 24269505
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Broadly protective immunity against divergent influenza viruses by oral co-administration of Lactococcus lactis expressing nucleoprotein adjuvanted with cholera toxin B subunit in mice.
    Lei H; Peng X; Jiao H; Zhao D; Ouyang J
    Microb Cell Fact; 2015 Aug; 14():111. PubMed ID: 26242406
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of membrane fusion activity of a whole inactivated influenza virus vaccine in (re)activation of influenza-specific cytotoxic T lymphocytes.
    Budimir N; Meijerhof T; Wilschut J; Huckriede A; de Haan A
    Vaccine; 2010 Dec; 28(52):8280-7. PubMed ID: 20965298
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Self-Amplifying mRNA Vaccines Expressing Multiple Conserved Influenza Antigens Confer Protection against Homologous and Heterosubtypic Viral Challenge.
    Magini D; Giovani C; Mangiavacchi S; Maccari S; Cecchi R; Ulmer JB; De Gregorio E; Geall AJ; Brazzoli M; Bertholet S
    PLoS One; 2016; 11(8):e0161193. PubMed ID: 27525409
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Peptide-loaded chimeric influenza virosomes for efficient in vivo induction of cytotoxic T cells.
    Amacker M; Engler O; Kammer AR; Vadrucci S; Oberholzer D; Cerny A; Zurbriggen R
    Int Immunol; 2005 Jun; 17(6):695-704. PubMed ID: 15843436
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influenza T-cell epitope-loaded virosomes adjuvanted with CpG as a potential influenza vaccine.
    Soema PC; Rosendahl Huber SK; Willems GJ; Jiskoot W; Kersten GF; Amorij JP
    Pharm Res; 2015 Apr; 32(4):1505-15. PubMed ID: 25344321
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enhancement of Th1 immune responses to recombinant influenza nucleoprotein by Ribi adjuvant.
    Cargnelutti DE; Sanchez MA; Alvarez P; Boado L; Mattion N; Scodeller EA
    New Microbiol; 2013 Apr; 36(2):145-51. PubMed ID: 23686120
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intranasal administration of a synthetic peptide vaccine encapsulated in liposome together with an anti-CD40 antibody induces protective immunity against influenza A virus in mice.
    Ninomiya A; Ogasawara K; Kajino K; Takada A; Kida H
    Vaccine; 2002 Aug; 20(25-26):3123-9. PubMed ID: 12163263
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Induction of cytotoxic T lymphocyte activity by fusion-active peptide-containing virosomes.
    Arkema A; Huckriede A; Schoen P; Wilschut J; Daemen T
    Vaccine; 2000 Jan; 18(14):1327-33. PubMed ID: 10618529
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Protein and modified vaccinia virus Ankara-based influenza virus nucleoprotein vaccines are differentially immunogenic in BALB/c mice.
    Altenburg AF; Magnusson SE; Bosman F; Stertman L; de Vries RD; Rimmelzwaan GF
    Clin Exp Immunol; 2017 Oct; 190(1):19-28. PubMed ID: 28665497
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influenza virosome/DNA vaccine complex as a new formulation to induce intra-subtypic protection against influenza virus challenge.
    Kheiri MT; Jamali A; Shenagari M; Hashemi H; Sabahi F; Atyabi F; Saghiri R
    Antiviral Res; 2012 Sep; 95(3):229-36. PubMed ID: 22809863
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunization with plasmid DNA encoding influenza A virus nucleoprotein fused to a tissue plasminogen activator signal sequence elicits strong immune responses and protection against H5N1 challenge in mice.
    Luo M; Tao P; Li J; Zhou S; Guo D; Pan Z
    J Virol Methods; 2008 Dec; 154(1-2):121-7. PubMed ID: 18789973
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improvement of the PapMV nanoparticle adjuvant property through an increased of its avidity for the antigen [influenza NP].
    Savard C; Laliberté-Gagné MÈ; Babin C; Bolduc M; Guérin A; Drouin K; Forget MA; Majeau N; Lapointe R; Leclerc D
    Vaccine; 2012 Mar; 30(15):2535-42. PubMed ID: 22326774
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effective Respiratory CD8 T-Cell Immunity to Influenza Virus Induced by Intranasal Carbomer-Lecithin-Adjuvanted Non-replicating Vaccines.
    Gasper DJ; Neldner B; Plisch EH; Rustom H; Carrow E; Imai H; Kawaoka Y; Suresh M
    PLoS Pathog; 2016 Dec; 12(12):e1006064. PubMed ID: 27997610
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cross-protection against influenza virus infection by intranasal administration of nucleoprotein-based vaccine with compound 48/80 adjuvant.
    Zheng M; Liu F; Shen Y; Wang S; Xu W; Fang F; Sun B; Xie Z; Chen Z
    Hum Vaccin Immunother; 2015; 11(2):397-406. PubMed ID: 25607884
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Heterosubtypic immunity to influenza mediated by liposome adjuvanted H5N1 recombinant protein vaccines.
    Thueng-in K; Maneewatch S; Srimanote P; Songserm T; Tapchaisri P; Sookrung N; Tongtawe P; Channarong S; Chaicumpa W
    Vaccine; 2010 Sep; 28(41):6765-77. PubMed ID: 20688037
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A novel role for non-neutralizing antibodies against nucleoprotein in facilitating resistance to influenza virus.
    Carragher DM; Kaminski DA; Moquin A; Hartson L; Randall TD
    J Immunol; 2008 Sep; 181(6):4168-76. PubMed ID: 18768874
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Incorporation of LpxL1, a detoxified lipopolysaccharide adjuvant, in influenza H5N1 virosomes increases vaccine immunogenicity.
    de Vries JJ; Bungener L; Ter Veer W; van Alphen L; van der Ley P; Wilschut J; Huckriede A
    Vaccine; 2009 Feb; 27(6):947-55. PubMed ID: 19059296
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.